文献速递皮肤肿瘤

前哨淋巴结活检状态改善临床IIB/C期黑色素瘤患者的辅助治疗决策:一项基于人群的分析

Sentinel lymph node biopsy status improves adjuvant therapy decision-making in patients with clinical stage IIB/C melanoma: A population-based analysis.
PubMed 文献 · J Am Acad Dermatol · 2022-11-25

研究基于监测、流行病学和最终结果数据库,纳入2004至2011年间接受广泛局部切除和前哨淋巴结活检的4391例临床IIB/C期皮肤黑色素瘤患者,比较含与不含前哨淋巴结状态的预后模型对5年黑色素瘤特异性死亡的预测效能。结果显示,含前哨淋巴结状态的模型在30%至78%治疗阈值下提供更高净获益,且在年龄和T分期亚组中持续存在;原文局限性为回顾性研究。

要点

  • 含前哨淋巴结状态的模型在30%至78%阈值下净获益优于不含该状态的模型。
  • 4391例患者中5年黑色素瘤特异性死亡率为46%。
  • 含前哨淋巴结状态模型的净获益优势在不同年龄组和T分期亚组中持续存在。

核心结论

  • 含前哨淋巴结状态、用于估计5年黑色素瘤特异性死亡风险的预后模型,在阈值死亡率≥30%时,净获益优于仅含原发肿瘤分期因素的模型。

研究设计与样本

  • 基于监测、流行病学和最终结果数据库的回顾性研究,纳入2004至2011年间接受广泛局部切除和前哨淋巴结活检的4391例临床IIB/C期皮肤黑色素瘤患者。
  • 开发了含与不含前哨淋巴结状态的两个预后模型,用于预测黑色素瘤特异性死亡风险;主要结局为5年黑色素瘤特异性死亡风险20%至40%治疗阈值下的净获益。

主要发现

  • 4391例患者的5年黑色素瘤特异性死亡率为46%。
  • 含前哨淋巴结状态的5年黑色素瘤特异性死亡风险估计模型,在30%至78%治疗阈值下,较不含前哨淋巴结状态的模型提供更高净获益。
  • 含前哨淋巴结活检模型的额外净获益在不同年龄组和不同T分期患者的亚组分析中持续存在。

局限性

  • 回顾性研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Given the results of the recent KEYNOTE-716 trial, the performance of sentinel lymph node (SLN) biopsy for patients with clinical stage IIB/C melanoma has been questioned. OBJECTIVE: Determine the utility of SLN status in guiding the recommendations for adjuvant therapy. METHODS: Patients with clinical stage IIB/C cutaneous melanoma who underwent wide local excision and SLN biopsy between 2004 and 2011 were identified from the Surveillance, Epidemiology, and End Results database. Two prognostic models, with and without SLN status, were developed predicting risk of melanoma-specific death (MSD). The primary outcome was net benefit at treatment thresholds of 20% to 40% risk of 5-year MSD. RESULTS: For the 4391 patients included, the 5-year MSD rate was 46%. The model estimating 5-year MSD risk that included SLN status provided greater net benefit at treatment thresholds from 30% to 78% compared to the model without SLN status. The added net benefit for the SLN biopsy-containing model persisted in subgroup analysis of patients in different age groups and with various T stages. LIMITATIONS: Retrospective study. CONCLUSIONS: A prognostic model with SLN status estimating patient risk for 5-year MSD provides superior net benefit compared to a model with primary tumor staging factors alone for threshold mortality rates ≥30%.

来源:J Am Acad Dermatol,查看原文。版权归原作者所有。

引用

  1. Sharon CE, Straker RJ, Gimotty PA, et al. Sentinel lymph node biopsy status improves adjuvant therapy decision-making in patients with clinical stage IIB/C melanoma: A population-based analysis. J Am Acad Dermatol. 2022. PMID: 36442639. doi:10.1016/j.jaad.2022.11.033

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。